The Alarming Rise of Medicalisation in India: From Public Health to Pharmaceutical Dependence

Editorial Summary The arrival of GLP-1 anti-obesity drugs at scale in India has reignited debate on the medicalisation of lifestyle conditions. With 47% out-of-pocket health expenditure and weak structural prevention (food labelling, sugar taxation, active transport), pharmacological solutions risk substituting for — rather than complementing — cheaper public-health measures. A regulatory framework that funds prevention first and regulates pharmaceutical pricing second is essential.

The Backdrop

GLP-1 receptor agonists — a class of drugs originally developed for type-2 diabetes — have emerged as blockbuster anti-obesity treatments over the past 3-5 years globally. Brand names familiar now in Indian metros:

• Ozempic / Wegovy (semaglutide; Novo Nordisk)
• Mounjaro / Zepbound (tirzepatide; Eli Lilly)
• Rybelsus (oral semaglutide)
• Indian biosimilars from Biocon, Dr Reddy’s, Lupin — under development; expected market entry 2026-27

These drugs produce 15-22% body weight loss over 6-12 months — clinical trial evidence is robust. But they are taken indefinitely (effect reverses on discontinuation), priced at ₹20,000-50,000/month in India, and carry significant side-effects.

The Medicalisation Thesis

Medicalisation is the process by which non-medical conditions (social, behavioural, environmental) are defined as medical problems requiring medical intervention. Applied to obesity:

• Pre-medicalisation framing: Obesity as a lifestyle condition addressable through diet, exercise, and environmental design (walkable cities, affordable fresh food, reduced UPF consumption)
• Medicalisation framing: Obesity as a chronic metabolic disease requiring lifelong pharmacological management

Both framings have partial truth — some obesity cases have genuine endocrine/metabolic roots; but most of India’s rising BMI is driven by food system and physical environment changes, not medical pathology.

The Concerns

1. Equity

• GLP-1 monthly cost (₹20,000-50,000) exceeds median Indian household monthly income
• Creates a two-tier health landscape
• Urban elite access, rural access near-zero

2. Sustainability

• Indefinite medication → lifelong drug dependence
• Reversal on discontinuation → unsuitable for periodic use
• Opportunity cost: resources spent on drugs unavailable for prevention

3. Side-effects and Secondary Pharma

• Sarcopenia (muscle loss) — requires BCAA supplementation
• Gastrointestinal (nausea, vomiting, constipation) — requires acid suppressants
• Gallbladder inflammation — requires cholesterol-lowering agents in some cases
• Psychiatric — depression, anxiety reported; SSRIs sometimes follow

Each side-effect creates a new market. The total lifetime pharmaceutical spend on managing GLP-1 therapy can be 2-3x the drug cost alone.

4. Regulatory Gaps

• FSSAI front-of-pack labelling — draft since 2019; still not mandatory
• Sugar tax — under discussion; no national implementation
• UPF (ultra-processed food) taxation — none
• Direct-to-consumer pharmaceutical advertising — CDSCO oversight weak
• Aggressive marketing to upper-middle-class urban consumers in tier-1 metros

The Cheaper Alternative — Public Health

International evidence strongly supports structural interventions:

India’s policy focus remains skewed toward treatment over prevention.

Ethical Dimensions

Autonomy vs Paternalism

• Individual right to access approved medications — legitimate
• But state has a duty to ensure structural conditions favour health
• Balance: regulate pharmaceutical pricing + advertising, don’t restrict access

Equity

• Treatments available to wealthy should not normalise a two-tier health landscape
• Requires DPCO inclusion of GLP-1 drugs once patent-expires
• India’s compulsory licensing regime (Section 84 Patents Act 1970) provides tool — used for Bayer’s Nexavar in 2012

Public-Health Ethics

• Mission LiFE’s environmental framing — sustainable diets, physical activity — aligns with structural prevention
• But requires parallel regulatory muscle — sugar/UPF taxation, food labelling, active-transport infrastructure

The Institutional Architecture Needed

1. CDSCO strengthening — Direct-to-consumer advertising rules, post-market surveillance
2. NPPA expansion — Include lifestyle drugs in price control; cap innovator-drug prices once critical mass reached
3. FSSAI reform — Mandate front-of-pack warning labels (similar to Chile model)
4. Finance Ministry action — Sugar and UPF taxation (GST Council)
5. MoHFW focus — National Action Plan on Obesity Prevention (currently absent)
6. Ministry of Housing & Urban Affairs — Active-transport infrastructure in AMRUT 2.0 and Smart Cities

Coordinated, this would address the root causes (food system, physical environment) rather than only the symptoms (individual weight).

UPSC Relevance